A PHASE I TRIAL OF SUBCUTANEOUS, OUTPATIENT INTERLEUKIN-2 FOR PATIENTS WITH MYELODYSPLASTIC SYNDROME (MDS)
- Determine the safety, tolerance, and maximum tolerated dose of subcutaneous
interleukin-2 (aldesleukin; IL-2) in patients with myelodysplastic syndrome (MDS).
- Evaluate the hematologic effects of subcutaneous IL-2 in MDS.
OUTLINE: IL-2 will be administered in cycles of twice daily subcutaneous injections 7 days a
week for 4 consecutive weeks. After each cycle the patient will be evaluated for response.
The patient could continue IL-2 therapy for up to 12 cycles. There are 4 dose levels of
IL-2. At each dose level 3 patients will be accrued sequentially.
Treatment with IL-2 should be continued until grade III toxicity or any side effects
requiring hospitalization occurs. After the patient returns to baseline pretherapy values or
grade I toxicity, the subject will resume IL-2 at 50% of the initial dose. If the patient
again goes into grade III toxicity or is in need of hospitalization, IL-2 will be
PROJECTED ACCRUAL: Between 12-24 patients will be accrued.
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
John A. Thompson, MD
Seattle Cancer Care Alliance
United States: Federal Government
|University of Washington Medical Center||Seattle, Washington 98195-6043|